Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Basilea Pharmaceutica

Evaluate

Thumbnail
November 02, 2022

If at first... pharma’s most drawn-out development timelines revealed

Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.

Thumbnail
September 07, 2020

Big pharma spinouts grow up

Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.

Article image
Vantage logo
January 09, 2020

Verastem plays the Kras card

For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.

Article image
Vantage logo
October 02, 2019

Esmo 2019 makes for a disappointing read-across to biotech

An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.

Article image
Vantage logo
July 10, 2019

Redx sells another asset to keep the lights on

The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.

Vantage logo
June 21, 2016

Interview – F2G’s novel antifungal brings in the bucks

Vantage logo
November 30, 2015

Basilea pins future on speciality business and US float

Vantage logo
July 09, 2013

Event – Basilea hopes its antifungal fits the mould

Vantage logo
February 18, 2013

Top licensing deals of 2012 – Glimmers of hope

Vantage logo
December 24, 2012

Midcap players ask Europe to bring it on in 2013

Vantage logo
November 13, 2012

Sun sets on DUSA’s independence as derma hots up

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up